All In Biotech

Drug Trial Radar · NCT02297594

Safety, Tolerability and PK Study of AK0529 in Healthy Human

A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of AK0529 When Administered Orally in Healthy Male and Female Adult Subjects

Last checked: Nov 20, 2026Latest source record: Oct 20, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

74

Actual

Start

Oct 2014

Primary completion

Jun 2015

Study completion Jun 2015

Sponsor

Sponsor type
Industry
First posted
Nov 21, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, tolerability and PK of single and multiple ascending dose of AK0529 when administered orally in healthy subjects

Conditions

  • Respiratory Syncytial Virus Infections

Interventions

  • AK0529Drug

    AK0529 capsule for oral administration

  • PlaceboDrug

    Sugar placebo capsule for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events, serious adverse eventsTime frame: Screening to Day 14 - 21

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Q-Pharm Pty Ltd QIMR Berghofer & Royal Brisbane and Women's Hospital Campus

    Brisbane, Queensland, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.